Ropeginterferon alfa-2b
Brand names: Besremi, Besremi Pen · Active ingredient: Ropeginterferon Alfa-2B
In short: BESREMi is indicated for the treatment of adults with essential thrombocythemia. BESREMi is indicated for the treatment of adults with polycythemia vera.
What is Ropeginterferon alfa-2b used for?
BESREMi is indicated for the treatment of adults with essential thrombocythemia.
BESREMi is indicated for the treatment of adults with polycythemia vera.
âš Boxed warning (FDA's strongest warning)
Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy .
Ropeginterferon alfa-2b dosage
Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with BESREMi .
Essential Thrombocythemia:
•The recommended dose of BESREMi is:
•A starting dose of 250 mcg by subcutaneous injection.
•At 2 weeks, increase the dose to 350 mcg by subcutaneous injection.
•At 4 weeks, increase to the maintenance dosage of 500 mcg by subcutaneous injection every 2 weeks.
•Maintain an every 2-week schedule throughout treatment unless dose modification is required for safety or tolerability.
•Consider dose re-escalation in case of prior dose reduction, recovery, and lack of hematologic response (platelets less than 400 × 109/L and leukocytes less than 10 × 109/L).
•Monitor complete blood counts every 2 weeks during titration and every 3 to 6 months during maintenance.
Polycythemia Vera:
Patients Not Already on Hydroxyurea
•The recommended BESREMi starting dosage for patients not on hydroxyurea is 100 mcg by subcutaneous injection every two weeks.
•Increase the dose by 50 mcg every two weeks (up to a maximum of 500 mcg), until the hematological parameters are stabilized (hematologic response: hematocrit less than 45%, platelets less than 400 × 109/L, and leukocytes less than 10 × 109/L).
•Consider dose re-escalation in case of prior dose reduction, recovery, and lack of hematologic response.
Patients Transitioning from Hydroxyurea
•When transitioning to BESREMi from hydroxyurea, start BESREMi at 50 mcg by subcutaneous injection every two weeks in combination with hydroxyurea.
•Gradually taper off the hydroxyurea by reducing the total biweekly dose by 20-40% every two weeks during Weeks 3-12.
•Increase the dose of BESREMi by 50 mcg every two weeks (up to a maximum of 500 mcg), until the hematological parameters are stabilized (hematocrit less than 45%, platelets less than 400 × 109/L, and leukocytes less than 10 × 109/L).
•Discontinue hydroxyurea by Week 13.
Maintain the two-week dosing interval of BESREMi at which hematological stability is achieved for at least 1 year. After achievement of hematological stability for at least 1 year on a stable dose of BESREMi, the dosing interval may be expanded to every 4 weeks.
Monitor patients closely especially during the titration phase. Perform complete blood counts (CBC) regularly, every 2 weeks during the titration phase and every 3-6 months during the maintenance phase (after the patient’s optimal dose is established). Monitor CBC more frequently if clinically indicated. Phlebotomy as rescue treatment to normalize blood hyperviscosity may be necessary during the titration phase .
Essential Thrombocythemia:
If dose interruption occurs, resume dosing at previously attained levels. …
How to take Ropeginterferon alfa-2b — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Depression and Suicide
Inform patients, their caregivers, and family members that suicidal ideation and behavior, as well as new onset or worsening depression have been reported in patients treated with BESREMi. Advise them to be aware of any unusual changes in mood or behavior, new onset or worsening of depression, or the emergence of suicidal thoughts or behavior. Instruct patients, caregivers, and family members to report signs or symptoms of depression to their healthcare provider right away, but to discontinue BESREMi immediately and seek immediate medical attention if suicidal ideation or attempts occur .
Endocrine Toxicity
Advise patients to report any signs or symptoms of diabetes or thyroid dysfunction .
Cardiovascular Toxicity
Advise patients to report signs or symptoms of cardiovascular toxicity to their healthcare provider .
Hematologic and Hemorrhagic Disorders
Advise patients to seek prompt medical attention if they experience weakness/fatigue, fever, easy bruising, or frequent nose bleeds . …
Warnings & precautions
Do not take this medicine if: BESREMi is contraindicated in patients with:
•Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt.
•Hypersensitivity to interferons including interferon alfa-2b or any of the inactive ingredients of BESREMi.
•Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
•History or presence of active serious or untreated autoimmune disease.
•Immunosuppressed transplant recipients.
Life-threatening or fatal neuropsychiatric reactions have occurred in patients receiving interferon alfa products, including BESREMi. These reactions may occur in patients with and without previous psychiatric illness. Psychiatric reactions have been observed in 10% of BESREMi-treated patients with essential thrombocythemia including depression, adjustment disorder with depressed mood, and depressed mood. Serious neuropsychiatric reactions have been observed in 3% of BESREMi-treated patients with polycythemia vera, including depression, depressive symptoms, depressed mood, and listlessness. Of these cases, 3.4% of the patients recovered with temporary drug interruption and 2.8% stopped BESREMi treatment.
Other central nervous system effects, including suicidal ideation, attempted suicide, aggression, bipolar disorder, mania and confusion have been observed with other interferon alfa products. BESREMi is contraindicated in patients with a history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt .
Closely monitor patients for any symptoms of psychiatric disorders and consider psychiatric consultation and treatment if such symptoms emerge. If psychiatric symptoms worsen, it is recommended to discontinue BESREMi therapy.
Endocrine toxicity has occurred in patients receiving interferon alfa products, including BESREMi. …
Ropeginterferon alfa-2b side effects
The following clinically significant adverse reactions are described elsewhere in the labeling.
•Depression and Suicide
•Endocrine Toxicity
•Cardiovascular Toxicity
•Hematologic and Hemorrhagic Disorders
•Hypersensitivity Reactions
•Pancreatitis
•Colitis
•Pulmonary Toxicity
•Ophthalmologic Toxicity
•Hyperlipidemia
•Hepatotoxicity
•Renal Toxicity
•Dental and Periodontal Toxicity
•Dermatologic Toxicity
•Driving and Operating Machinery
•Embryo-Fetal Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Essential Thrombocythemia
The pooled safety population described in the Warnings and Precautions section reflects exposure to BESREMi as monotherapy for the treatment of essential thrombocythemia dosed every 2 weeks in 182 patients in an open-label trial [P1101 ET, SURPASS ET] and a single-arm trial [A22-301, EXCEED ET]. The mean age was 56 years (range: 21 to 84 years). There were 104 (57%) women, 78 (43%) men, and 93 (51%) Asian, 76 (42%) Caucasian, 5 (2.7%) Black or African American, 5 (2.7%) Other, and 3 (1.6%) Hispanic patients were included in the studies. Among 182 patients who received BESREMi, 70 (39%) patients were exposed for >56 weeks (>14 months). The mean (SD) dose of BESREMi was 394.9 (98.4) mcg during the treatment period. …
Drug interactions
Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates . Therefore, patients on BESREMi who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index should be monitored to inform the need for dosage modification for these concomitant drugs.
Concomitant use of BESREMi and myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression .
Concomitant use of BESREMi and narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity .
About this medicine
Ropeginterferon alfa-2b-njft, an interferon alfa-2b, is an N-terminal monopegylated covalent conjugate of proline interferon alfa-2b, produced in Escherichia coli cells by recombinant DNA technology, with a methoxy polyethylene glycol (mPEG) moiety. Ropeginterferon alfa-2b-njft has an approximate molecular weight of 60 kDa and the approximate molecular weight of the PEG portion of the molecule is 40 kDa.
BESREMi (ropeginterferon alfa-2b-njft) injection is a sterile, clear and colorless to slightly yellowish solution for subcutaneous use supplied in a single-dose prefilled syringe or in a single-dose prefilled pen injector.
Each prefilled syringe delivers 1 mL of solution containing 500 mcg of ropeginterferon alfa-2b-njft and benzyl alcohol (10 mg), glacial acetic acid (0.05 mg), polysorbate 80 (0.05 mg), sodium acetate (1.58 mg), sodium chloride (8 mg), and Water for Injection, USP. The pH is approximately 6. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9583405d-53a0-49dc-88eb-5e6384ebabcb. Read the full official label on DailyMed.